Immunological responses to adjuvant vaccination with combined CD1c(+) myeloid and plasmacytoid dendritic cells in stage III melanoma patients.
Immunological responses to adjuvant vaccination with combined CD1c(+) myeloid and plasmacytoid dendritic cells in stage III melanoma patients.
复制标题
DOI：
10.1080/2162402x.2021.2015113
复制
发表时间：
2022
期刊：
影响因子：
7.2
通讯作者：
中科院分区：
文献类型：
--
作者：
我们评估了淋巴结病变（III期）黑色素瘤患者对天然树突状细胞亚群（ndc）辅助树突状细胞疫苗的免疫反应。15例完全切除的III期黑色素瘤患者随机接受CD1c+髓样树突状细胞（cDC2s）、浆细胞样树突状细胞（pDCs）或两者结合的佐剂树突状细胞疫苗接种。免疫应答是主要终点，次要终点包括安全性和生存期。在80%的患者中，在皮肤测试衍生的T细胞中检测到抗原特异性CD8+ T细胞，在55%的患者中，外周血中检测到抗原特异性CD8+ T细胞。在64%的患者皮肤试验中发现功能性干扰素γ产生T细胞。生产符合放行标准的nDC疫苗对所有患者都是可行的。接种疫苗只会引起1-2级不良反应，主要是疲劳。综上所述，cDC2s和/或pDCs佐剂树突状细胞疫苗接种在大多数III期黑色素瘤患者中是可行、安全且诱导免疫应答的。
We evaluated the immunological responses of lymph-node involved (stage III) melanoma patients to adjuvant dendritic cell vaccination with subsets of naturally occurring dendritic cells (nDCs). Fifteen patients with completely resected stage III melanoma were randomized to receive adjuvant dendritic cell vaccination with CD1c+ myeloid dendritic cells (cDC2s), plasmacytoid dendritic cells (pDCs) or the combination. Immunological response was the primary endpoint and secondary endpoints included safety and survival. In 80% of the patients, antigen-specific CD8+ T cells were detected in skin test-derived T cells and in 55% of patients, antigen-specific CD8+ T cells were detectable in peripheral blood. Functional interferon-γ-producing T cells were found in the skin test of 64% of the patients. Production of nDC vaccines meeting release criteria was feasible for all patients. Vaccination only induced grade 1–2 adverse events, mainly consisting of fatigue. In conclusion, adjuvant dendritic cell vaccination with cDC2s and/or pDCs is feasible, safe and induced immunological responses in the majority of stage III melanoma patients.